Drugs / High-dose methylprednisolone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04862221 | Feb 2022 → Aug 2026 overdue | acute liver failure, hepatic encephalopathy, immune dysregulation, autoimmunity, and autoinflammation | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-dose methylprednisolone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04862221 ↗ |
| Route | Intravenous | “methylprednisolone IV 10 mg/kg/day” NCT04862221 ↗ |